Name

CBI

Alternate names

None

Primary Site

None

Histology

None

Radiation

None

Remarks

None

Drugs for CBI

Name

Alternate Names

Avastin
rhuMAB-VEGF

Abbreviations

None

Category

Biologic therapy (BRM, immunotherapy)

Subcategory

Cytostatic agent--antiangiogenesis agent
Recombinant human anti-VEGF.
Vascular endothelial growth factor receptor inhibitor

NSC Number

704865

Primary Site

Breast- see remarks
Fallopian tube
Ovary
Peritoneum
colorectal
kidney
lung
multiple myeloma
Brain

Histology

None

Remarks

JANUARY 2013 IMPORTANT UPDATE: This drug has changed categories. A comprehensive review has been completed and in keeping with the FDA, this drug is to be coded as a Biologic therapy/Immunotherapy agent. Effective with diagnosis date January 1, 2013 forward, code Avastin as BRM/Immunotherapy. For cases diagnosed prior to January 1, 2013 continue coding this drug as chemotherapy.

FDA has formally revoked its approval of this drug to treat breast cancer. Physicians may still prescribe it but insurers may not pay for it.
FDA approved for colorectal cancer.
FDA approved for treatment of persistent, recurrent or metastatic cervical cancer in combination with paclitaxel and cisplatin or paclitaxel and topotecan.
Nov. 2014: FDA approved in combination with paclitaxel, doxorubicin, or topotecan for the treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
In clinical trials Phase II and III for multiple myeloma
December 12, 2016: Avastin received FDA approval to be used either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine chemotherapy, followed by Avastin alone, for treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer.

6/15/18: FDA has approved bevacizumab (Avastin) for patients with epitheliĀ¬al ovarian, fallopian tube, or primary peritoneal cancer in combination with carboplatin and paclitaxel, followed by single-agent bevacizumab, for stage III or IV disease after initial surgiĀ¬cal resection


June 13, 2018: FDA approved bevacizumab (Avastin) for patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer in combination with carboplatin and paclitaxel, followed by single-agent bevacizumab, for stage III or IV disease after initial surgical resection.

December 6, 2017: FDA has granted full approval for Avastin (bevacizumab) for the treatment of adults with glioblastoma that progressed following prior therapy

Coding

This drug should be coded

Name

Alternate Names

C 225
C-225
C225
Erbitux
IMC-C225

Abbreviations

None

Category

Biologic therapy (BRM, immunotherapy)

Subcategory

Monoclonal antibody, anti-EGFR antibody

NSC Number

714692

Primary Site

Breast
colorectal
head & neck
lung
ovarian
pancreatic cancer

Histology

None

Remarks

JANUARY 2013 IMPORTANT UPDATE: This drug has changed categories. A comprehensive review has been completed and in keeping with the FDA, cetuximab is to be coded as a Biologic therapy/Immunotherapy agent. Effective with diagnosis date January 1, 2013 forward, code cetuximab as BRM/Immunotherapy. For cases diagnosed prior to January 1, 2013 continue coding this drug as chemotherapy.

FDA approved colorectal 2004, head and neck 2006; orphan drug for pancreas
Anti-VEGFr chimeric monoclonal antibody.

Coding

This drug should be coded

Name

Alternate Names

Camptosar
Camptosar Oral
Camptothecin-11
CPT 11
CPT-11
CPT11
U-101440E

Abbreviations

None

Category

Chemotherapy

Subcategory

Topoisomerase inhibitor

NSC Number

616348

Primary Site

Colorectal
head & neck
Non-small cell lung cancer (NSCLC)
pancreatic cancer
Small cell lung cancer (SCLC)

Histology

None

Remarks

Phase I (head & neck) Phase III SCLC pancreatic Topoisomerase I inhibitor. FDA approved use on colorectal cancer. Pharmacia.

Coding

This drug should be coded
Glossary